LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Incyte Corp

Chiusa

SettoreSettore sanitario

61.16 0.63

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

59.89

Massimo

62.22

Metriche Chiave

By Trading Economics

Entrata

-43M

158M

Vendite

-126M

1.1B

P/E

Media del settore

304.25

56.602

EPS

1.16

Margine di Profitto

15.025

Dipendenti

2,617

EBITDA

-80M

257M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+21.46% upside

Dividendi

By Dow Jones

Utili prossimi

29 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.3B

12B

Apertura precedente

60.53

Chiusura precedente

61.16

Notizie sul Sentiment di mercato

By Acuity

36%

64%

117 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2025, 23:40 UTC

Azioni calde

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mag 2025, 23:33 UTC

I principali Market Mover

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mag 2025, 23:25 UTC

I principali Market Mover

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mag 2025, 23:25 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 22:58 UTC

Utili

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 21:35 UTC

Utili

Cisco Systems Names Patterson as CFO, Patel as President

14 mag 2025, 23:59 UTC

Discorsi di Mercato

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mag 2025, 23:49 UTC

Discorsi di Mercato

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Gains on Possible Technical Recovery -- Market Talk

14 mag 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mag 2025, 23:10 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mag 2025, 23:07 UTC

Utili

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mag 2025, 23:00 UTC

Notizie principali

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mag 2025, 22:43 UTC

Utili

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mag 2025, 22:34 UTC

Utili

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mag 2025, 22:33 UTC

Utili

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mag 2025, 22:30 UTC

Utili

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mag 2025, 22:28 UTC

Utili

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mag 2025, 22:27 UTC

Utili

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mag 2025, 22:23 UTC

Notizie principali

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mag 2025, 22:15 UTC

Utili

Correction to Cisco Earnings Article -- WSJ

14 mag 2025, 21:48 UTC

Utili

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mag 2025, 21:37 UTC

Utili

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

21.46% in crescita

Previsioni per 12 mesi

Media 73.86 USD  21.46%

Alto 95 USD

Basso 52 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

6

Acquista

11

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

59.52 / 62.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

117 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation